Two more blood pressure medications recalled for ingredient that might cause cancer

New high blood pressure guidelines mean 30 million more Americans have hypertension

Under the new guidelines, the number of adults with high blood pressure will rise to 103 million from 72 million. Hypertension is the leading cause of heart disease and heart-related deaths in the U.S. and worldwide.

By

Up Next

Under the new guidelines, the number of adults with high blood pressure will rise to 103 million from 72 million. Hypertension is the leading cause of heart disease and heart-related deaths in the U.S. and worldwide.

By

The list of blood pressure drugs recalled because they have NDEA grew by two Tuesday when Teva Pharmaceuticals yanked all lots of Amlodipine/Valsartan and Amlodipine/Valsartan/Hydrochlorothiazide combination tablets.

Both have too much N-nitroso-diethylamine (NDEA) in its Valsartan, the active ingredient made by Mylan India. NDEA has been classified as a probable cancerous ingredient by the International Agency for Research on Cancer.

More NDEA than allowed prompted Mylan’s recall of 15 heart attack and blood pressure medications last week, as well as Sandoz’s recall of Losartan blood pressure meds on Nov. 8 and July’s slew of Valsartan blood pressure drug recalls.

As with previous recalls, the company-written, FDA-posted recall notice advises continuing to take the recalled drugs until the patient and a medical professional agree on another course of action.